Merck, Modifi

Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 billion
Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday. As part of the deal, the U.S.
Merck Acquires Modifi Biosciences
Modifi Biosciences, Inc., a leader in the development of direct DNA modification enabled cancer therapeutics, has been acquired by Merck.
Merck sets sights on brain cancer with $30M Modifi acquisition
Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma.
Merck acquires Modifi Biosciences in $1.3bn cancer therapy deal
The acquisition strengthens Merck's oncology portfolio as the company looks to off the expiration of the patent for pembrolizumab.
Merck buys Modifi for $30M plus up to $1.3B in potential payments
Merck (NYSE:MRK) has acquired Modifi Biosciences, a developer of DNA modification-enabled cancer drugs, for $30M upfront and up to $1.3B in potential milestone payments. Modifi, a spinout of Yale University,
Merck acquires Yale-spinout Modifi Bio in $1.3B deal
Modifi Biosciences, a New Haven startup biotech that focuses on developing cancer therapies, has been acquired by biopharmaceutical giant Merck & Co. Inc. in a $1.3 billion deal, the companies announced Wednesday.
Merck & Co buys Modifi Biosciences
Connecticut, USA-based Modifi Biosciences today announced that the company has been acquired by pharma giant Merck & Co (NYSE: MRK). Modifi Biosciences was formed in 2021 based on technology spun out of Yale University.
MSD acquires cancer therapeutics developer Modifi Biosciences
MSD has acquired US cancer therapeutics developer Modifi Biosciences, a Yale University spinout, enhancing its portfolio with preclinical compounds designed to target DNA repair defects in hard-to-treat cancers.
Merck acquires Modifi Biosciences for $30M upfront
Modifi Biosciences announced that the company has been acquired by Merck (MRK). Under the terms of the agreement Merck, through a subsidiary,
Merck Buys Yale Cancer-Therapy Spinout Modifi Biosciences
Modifi on Wednesday said the deal gives Rahway, N.J., drugmaker Merck access to preclinical compounds designed to exploit DNA repair defects in hard-to-treat cancers, including glioblastoma, the most aggressive type of brain tumor.
Outsourcing-pharma10h
Merck acquires cancer startup in a deal worth up to $1.3 billion
Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair ...
manilatimes1d
Modifi Biosciences Acquired by Merck
Under the terms of the agreement Merck, through a subsidiary, has acquired all outstanding shares of Modifi Biosciences for ...
BioPharma Dive1d
Merck acquires cancer drug startup; Elevidys ex-US sales rise
Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...
Bank of America Securities Sticks to Their Buy Rating for Merck & Company (MRK)
In a report released today, Charlie CY Yang from Bank of America Securities maintained a Buy rating on Merck & Company (MRK – ...